Get the Stockscreener App
0.00
100.00%
-8.68
Sage Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$8.68
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$544.94M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
0.00
EPS:
-8.39
Net Cash Flow:
$-424.74M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$9.36
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare SAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
0.00 | 544.94M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-25 | Resumed | BofA Securities | Underperform |
| Nov-21-24 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-04-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-29-24 | Initiated | Citigroup | Sell |
| May-29-24 | Initiated | Robert W. Baird | Neutral |
| Apr-17-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
| Aug-08-23 | Downgrade | Needham | Buy → Hold |
| Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-07-23 | Downgrade | Stifel | Buy → Hold |
| Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Mar-31-22 | Initiated | Berenberg | Hold |
| Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-07-21 | Initiated | Piper Sandler | Overweight |
| Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
| Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Resumed | Raymond James | Mkt Perform |
| Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
| Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
| Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-05-19 | Reiterated | Guggenheim | Buy |
| Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
| Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
| May-23-19 | Initiated | Wedbush | Outperform |
| Apr-25-19 | Initiated | Jefferies | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
Published on: 2025-08-21 00:14:22 - thegnnews.com
Sage Therapeutics Inc. Enters Reversal Setup in Weekly ChartsMarket Activity Recap & Fast Entry Momentum Trade Alerts - newsyoung.net
Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace
Postpartum Depression Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb - Barchart.com
What is the long term forecast for Sage Therapeutics Inc. stockLong Setup & Risk Adjusted Buy and Sell Alerts - thegnnews.com
Can Sage Therapeutics Inc. be recession proofStocks with Huge Upside Movement - thegnnews.com
SUPERNUS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Supernus Pharmaceuticals Announces Q2 2025 Financial Results and Acquisition of Sage Therapeutics - Quiver Quantitative
Supernus Announces Second Quarter 2025 Financial Results - GlobeNewswire
MACD Cross Could Confirm Trend in Sage Therapeutics Inc.Profit Focused Stock Screener Results Released - beatles.ru
Sage Therapeutics (NASDAQ:SAGE) Rating Increased to Hold at Wall Street Zen - MarketBeat
Is it the right time to buy Sage Therapeutics Inc. stockUnlock powerful market trend analysis - Jammu Links News
How volatile is Sage Therapeutics Inc. stock compared to the marketConsistently high returns - Jammu Links News
What is the dividend policy of Sage Therapeutics Inc. stockHigh-octane financial growth - Jammu Links News
Is Sage Therapeutics Inc. a growth stock or a value stockGet alerts on high-potential stock breakouts - Jammu Links News
Why is Sage Therapeutics Inc. stock attracting strong analyst attentionCapitalize on market shifts with expert advice - Jammu Links News
What are the latest earnings results for Sage Therapeutics Inc.Free Investment Timing Strategies - Jammu Links News
How strong is Sage Therapeutics Inc. company’s balance sheetGet daily expert analysis on top stocks - Jammu Links News
When is Sage Therapeutics Inc. stock expected to show significant growthStrongest growth potential - Jammu Links News
What institutional investors are buying Sage Therapeutics Inc. stockExtraordinary market timing - Jammu Links News
What are Sage Therapeutics Inc. company’s key revenue driversCapitalize on high-yield stock opportunities - Jammu Links News
What makes Sage Therapeutics Inc. stock price move sharplyHigh-velocity gains - Jammu Links News
Supernus Acquires Sage Therapeutics to Strengthen Neuropsychiatric Portfolio - AInvest
Sage (SAGE) Q2 Revenue Jumps 264% - AOL.com
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and ZimVie Inc (ZIMV) - The Globe and Mail
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics - Yahoo Finance
SAGE Therapeutics Announces Nasdaq Delisting Following Merger and Board Changes - AInvest
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Supernus completes acquisition of Sage Therapeutics for $8.50 per share By Investing.com - Investing.com Nigeria
Supernus completes acquisition of Sage Therapeutics for $8.50 per share - Investing.com Australia
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire
Supernus Pharmaceuticals Acquires Sage Therapeutics to Strengthen Presence in Neuropsychiatric Conditions - AInvest
Supernus' $200M Sage Therapeutics Acquisition Adds First-Ever Oral Postpartum Depression Drug - Stock Titan
Sage Therapeutics 2025 Q2 Earnings Significant Revenue Growth as Net Income Loss Narrows 51.7% - AInvest
Sage Therapeutics Announces Second Quarter 2025 Financial Results - BioSpace
SAGE Therapeutics earnings beat by $0.15, revenue topped estimates - Investing.com Canada
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Sage Therapeutics Announces Second Quarter 2025 Financial Results | SAGE Stock News - GuruFocus
Market reaction to Sage Therapeutics Inc.’s recent newsWeekly Stock Opportunity Radar Scanner Activated - metal.it
Supernus Pharmaceuticals Announces Expiration of HSR Waiting Period for Sage Therapeutics Acquisition - AInvest
Sage Therapeutics Acquisition Advances Amid Antitrust Review Expiration and Analyst Forecasts - AInvest
Cwm LLC Buys 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Published on: 2025-07-29 04:12:23 - metal.it
Supernus Pharmaceuticals Announces Expiration of - GlobeNewswire
Supernus announces expiration of HSR waiting period for Sage Therapeutics - TipRanks
SAGE Acquisition Advances as Antitrust Waiting Period Ends - GuruFocus
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - The Manila Times
Supernus Pharmaceuticals Announces Expiration of HSR Waiting Period for Acquisition of Sage Therapeutics - Quiver Quantitative
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.55%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):